Skip to content
Review

Cuproptosis: The metabolic-immune axis in chronic obstructive pulmonary disease pathogenesis and therapeutics.

Aug 2026 · International Immunopharmacology · Vol 188, pp. 117289 · 0 citations · 97 references
Medicine

TL;DR

It is argued that the cuproptosis-immune axis warrants systematic exploration as a potential target for disease-modifying therapy, while acknowledging the substantial hurdles that must be overcome before clinical translation can be contemplated.

Abstract

Chronic Obstructive Pulmonary Disease (COPD) remains a leading cause of global morbidity and mortality, characterized by progressive airflow limitation and chronic inflammation that current therapies fail to effectively modify. The recent discovery of cuproptosis-a copper-dependent, regulated cell death mechanism driven by mitochondrial proteotoxic stress-provides a compelling framework to reinterpret COPD pathophysiology. In this review, we advance the hypothesis that cuproptosis functions not merely as a passive consequence but as a critical amplifier within a self-sustaining "Metabolic-Immune Cell Death Axis" that drives disease chronicity and progression. We synthesize evidence demonstrating that cigarette smoke actively disrupts pulmonary copper homeostasis, creating a microenvironment permissive for cuproptosis. Central to our model is a vicious cycle wherein cuproptotic death of structural cells releases immunogenic damage-associated molecular patterns (DAMPs) that fuel neutrophilic inflammation and pro-inflammatory macrophage polarization; in turn, this inflammatory milieu further impairs copper handling in surviving cells, sensitizing them to subsequent death. A key determinant of this process is cellular metabolic dependency-cells reliant on oxidative phosphorylation (such as alveolar type II epithelial cells and anti-inflammatory M2 macrophages) are predicted to be exquisitely vulnerable. Transitioning from mechanism to transitional potential, we survey cuproptosis-related biomarkers and emerging therapeutic strategies-including lung-targeted copper chelators, ionophores, nanoplatforms, and PROTAC-based sensitizers-while explicitly distinguishing established evidence from speculative hypotheses. Critically, we emphasize that all these approaches remain at preclinical or early exploratory stages, with no clinical trials yet conducted in COPD. By delineating a roadmap for future investigation-prioritizing direct human evidence, biomarker validation, and rigorous preclinical safety studies-we argue that the cuproptosis-immune axis warrants systematic exploration as a potential target for disease-modifying therapy, while acknowledging the substantial hurdles that must be overcome before clinical translation can be contemplated.

View source

Similar papers

Review Open access Sep 2026

Mitophagy in idiopathic pulmonary fibrosis: from molecular mechanisms to therapeutic opportunities

This review systematically dissects the regulatory networks governing mitophagy, encompassing the canonical PINK1/Parkin pathway, receptor-mediated mechanisms, and their intricate cross-talk with endoplasmic reticulum stress (ERS) and ferroptosis, highlighting how these interconnected pathways converge to determine alv...

Meng-Zhu He, Yi Li, Hong Huang et al. · 0 citations
Review Open access Sep 2026

Neutrophil extracellular traps in asthma and chronic obstructive pulmonary disease: pathogenic roles, and therapeutic opportunities

The components of NETs, the molecular mechanisms underlying NET formation, the interplay between NETs and T cells, current findings on the role of NETs in asthma and COPD, and emerging NET-targeted therapeutic strategies are summarized.

Xi-Jie Zhang, Tobias Dallenga, Susanne Krauss-Etschmann · 1 citation
Review Sep 2026

[Advances in the mechanistic researches of neutrophil extracellular trap in pulmonary diseases].

This review systematically summarizes the mechanisms of NET formation, metabolic regulation, autophagy, and their interactions with platelets and provides an in-depth discussion of the roles and clinical significance of NET in both acute and chronic pulmonary diseases.

Zhi-Liang Fan, Yi-Hui Chai, Qian Li et al. · 0 citations
Open access Oct 2026

How Innate Immune Mechanisms Contribute to the Chronic Nature of COPD?

Background Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent inflammation, airflow limitation, and progressive tissue destruction. While smoking is a major risk factor, recent research links innate immune mechanisms, oxidative stress, and protease imbalances to disease chronicity. Objectives T...

B. M. Khashman, Yasir M. Abdulateef, H. N. Eyada · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.